SCHEMBL25033085

SCHEMBL25033085

C#CCNc1ccc(P(C)(C)=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.51
▸ CA9 Q16790 3/20 0.51
▸ CA2 P00918 3/20 0.51
▸ MAPT P10636 2/20 0.51
▸ CA1 P00915 2/20 0.51
▸ MAOA P21397 3/20 0.42
▸ MAOB P27338 3/20 0.42
▸ LMNA P02545 1/20 0.42
▸ MMP9 P14780 1/20 0.39
▸ MMP13 P45452 1/20 0.39
▸ ADAM17 P78536 1/20 0.39
▸ CA4 P22748 1/20 0.39
▸ HPGD P15428 1/20 0.34
▸ KCNH3 Q9ULD8 1/20 0.34
▸ HKDC1 Q2TB90 1/20 0.31
▸ SRC P12931 2/20 0.31
▸ ESR1 P03372 1/20 0.31
▸ CA14 Q9ULX7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10312074 0.78 LMNA (0.66) MAPTLMNAHPGDHKDC1SRC
SCHEMBL31592520 0.75 CA12 (0.53) CA12CA9CA2MAPTCA1
SCHEMBL31104501 0.74 CA12 (0.41) CA12CA9CA2MAPTCA1
SCHEMBL25033427 0.73 MAOA (0.35) CA12CA9CA2MAPTCA1
SCHEMBL25030921 0.73 MAPT (0.31) CA12CA9CA2MAPTCA1
SCHEMBL11741377 0.73 MAPT (0.58) CA12CA9CA2MAPTCA1
SCHEMBL11078522 0.71 MAPT (0.53) CA12CA9CA2MAPTCA1
SCHEMBL17076659 0.71 CA12 (0.58) CA12CA9CA2MAPTCA1
SCHEMBL566097 0.71 MAPT (0.53) CA12CA9CA2MAPTCA1
SCHEMBL4225554 0.71 CA12 (0.53) CA12CA9CA2MAPTCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119968361-A Compounds targeting p 53Y 220 mutants 北京加科思新药研发有限公司 2025-05-09 — — CN disclosed
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-12-05 — — US disclosed
EP-4384510-A1 COMPOUNDS TARGETING MUTANT OF P53 Jacobio Pharmaceuticals Co., Ltd. (CN) 2024-06-19 — — EP disclosed
CN-117813295-A Compounds targeting p53 mutants 北京加科思新药研发有限公司 2024-04-02 — — CN disclosed
WO-2024041503-A1 COMPOUNDS TARGETING Y220C MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-02-29 — — WO disclosed
WO-2023016434-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2023-02-16 — — WO disclosed
WO-2023016434-A1 COMPOUNDS TARGETING MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2023-02-16 — — WO disclosed
WO-2022213975-A1 COMPOUNDS TARGETING Y220C MUTANT OF P53 JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2022-10-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400591-A1 COMPOUNDS TARGETING MUTANT OF P53 TP53, TP53BP1, MDM2 CA12 3295/4885CA9 3658/4885CA2 3601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback